| |
July 18-19, 2023 | Jersey City, NJ This is the only communications event for peer learning and networking exclusively for the life science community.
Only two weeks left to Register!
|
|
Today's Big NewsJul 7, 2023 |
|
October 16-18, 2023 | Boston, MA The event is created with networking in mind and several opportunities where you can meet, connect and engage with your peers and grow your network. Save $346 on Registration with the Early Bird Rate!
|
|
| By Fraiser Kansteiner With a full approval in hand, Leqembi has become the first treatment shown to reduce the rate of disease progression and slow cognitive and functional decline in adults with Alzheimer’s disease under the FDA's traditional approval pathway. Now, the companies can start with their wider launch effort. |
|
|
|
By Gabrielle Masson Eli Lilly’s Prevail Therapeutics has changed up a licensing agreement with gene therapy biotech Precision Therapeutics, dropping the biobucks value and seeking a bigger share of pre-clinical duties. |
By Nick Paul Taylor BrainStorm Cell Therapeutics has latched on to the recent accelerated FDA approval of Biogen and Ionis’ amyotrophic lateral sclerosis (ALS) drug to make the case that its cell therapy could join the rival product on the U.S. market. |
By James Waldron After joining forces last year to work on an antibody-drug conjugate to treat brain cancer, China’s GeneQuantum Healthcare and South Korea’s Aimed Bio are expanding their partnership to encompass up to five more therapies. |
By Annalee Armstrong Scientists have long known that cancer cells typically have extra chromosomes, but what exactly was the extra genetic material doing? New research from a team at Yale University has finally provided an answer. |
By Gabrielle Masson They say people begin to look like their dogs over time, but what about their cancers? New findings have revealed previously undetected genetic similarities between dog and human cancers. |
By Max Bayer,Gabrielle Masson Merck KGaA veteran Miguel Fernández Alcalde is jumping across the pond to be chief operating officer of the company's U.S. wing, EMD Serono. |
By Teresa Carey This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines. |
By Kevin Dunleavy In late May, the FDA warned of illegal knockoffs of Novo Nordisk’s Ozempic and Wegovy. And now, the Danish company has filed its second wave of lawsuits against pharmacies in the U.S. that are producing the copycats. |
By Andrea Park Less than a year after it was flooded with $100 million in venture capital, and just as a new trial of its energy therapy technology ramps up, Galvanize Therapeutics is now undergoing a decidedly less exciting update. |
By Nick Paul Taylor AstraZeneca’s asthma marketing team is pushing the importance of inflammation in asthma. Across two unbranded campaigns targeting patients and healthcare professionals, the drugmaker is communicating a message that is aligned with the effects of its recently approved rescue inhaler Airsupra. |
By Heather Landi The White House proposal would reverse a controversial Trump-era rule that expanded the duration of short-term health plans, or what critics refer to as "junk" plans. |
By Andrea Park There’s something fishy about Coloplast’s latest megadeal—literally. The Danish medtech announced plans on Friday to acquire Kerecis, which uses fish skin as the basis of its wound care products for humans. |
By Angus Liu AstraZeneca and Daiichi Sankyo delivered a concerning safety message for their TROP2 antibody-drug conjugate. Moderna reportedly plans to invest up to $1 billion in China. Takeda expanded its antibody partnership with F-Star Therapeutics with a new deal potentially worth $1 billion. And more. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we discuss new HIV therapies, plus Humira's new biosimilar, foreign pharmaceutical investments, and the rest of the week's headlines. |
|
|---|
|
|
| ResearchThe right sourcing strategy can help save of millions of dollars—learn about developing a strategy for sourcing the cGMP chemicals critical to your processes. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperLearn how a GPCR-focused library with a cell-based biopanning strategy led to the discovery of 13 high-affinity and selective anti-GLP-1R antibodies with highly developable therapeutic properties. Sponsored by: Twist Bioscience |
| eBookThis eBook identifies the trends driving major change in the Medical Affairs (MA) function. It also outlines the strategic and tactical implications for MA leaders and team members. Sponsored by: Blue Matter, strategic consultants in the life sciences |
| eBookTake a look at the reporting tools sponsors need to access insights earlier in the clinical trial enrollment funnel, so you can take informed actions. Sponsored by: OneStudyTeam |
| WhitepaperLearn how to develop a high-performing supply chain for cGMP chemicals used throughout your bioprocessing workflows. Sponsored by: Thermo Fisher Scientific Production Chemicals and Services |
| WhitepaperExplore how clinical supply can be scaled up as decentralized programs progress, and how technological solutions can accelerate trial deployment. Sponsored by: Catalent Clinical Supply |
| WhitepaperPlanning on using a CRO to support your next clinical study? This infographic outlines critical areas to address at the start of the relationship in order to ensure that budget and timelines keep on track for the duration of the trial. Sponsored by: Catalent |
| |
|
